The RE-ENERGIZE Study: RandomizEd Trial of ENtERal Glutamine to minimIZE Thermal Injury



Status:Recruiting
Conditions:Other Indications, Hospital
Therapuetic Areas:Other
Healthy:No
Age Range:18 - Any
Updated:8/31/2018
Start Date:December 2010
End Date:December 2021
Contact:Maureen Dansereau
Email:maureen.dansereau@kingstonhsc.ca
Phone:613 549 6666

Use our guide to learn which trials are right for you!

Effects of Enteral Glutamine Supplementation on Mortality and Infectious Morbidity in Severely Burned Patients: a Multi-center Pilot Trial

The purpose of this study is to test the following hypotheses:

1. Enteral glutamine administration decreases in-hospital mortality in adult patients with
severe thermal burn injuries.

2. Enteral glutamine administration decreases hospital-acquired blood stream infections
from Gram negative organisms and length of stay in ICU and hospital for adult patients
with severe thermal burn injuries.

3. Enteral glutamine administration will improve the physical function of surviving burn
injured patients and reduce their cost of care.

The objectives of this trial are to determine the overall treatment effect and safety of
glutamine in burn patients. Specifically, the investigators want to assess the following
outcomes in a sample of 2,700 patients in 80 sites:

1. In patients with severe, life-threatening burn injury, what is the effect of enteral
glutamine on 6 month mortality?

2. In patients with severe, life-threatening burn injury, what is the effect of enteral
glutamine on time to discharge alive from hospital, hospital-acquired blood stream
infections from Gram negative organisms, hospital mortality, duration of stay in ICU and
hospital, health-related quality of life, and health care resources?

Burn injuries represent a public health problem worldwide, ranked fourth in all injuries and
are among the leading cause of disability adjusted life years in low and middle-income
countries. More than in any other injury, the inflammation and catabolism associated with
severe burns can exacerbate nutrient deficiencies, thereby predisposing patients to impaired
immune function and increased risk of developing infectious complications, organ dysfunction,
and death. Consequently, over the last few decades numerous trials have evaluated the impact
of different nutrition/nutrient strategies in severe burns patients. Glutamine is of
particular interest in this regard as it appears vital for a number of key stress-response
pathways in serious illness. The existing randomized trials of glutamine supplementation in
burns patients have suggested a significant reduction in mortality, infection, and hospital
length of stay. However, in other critically ill patient populations, there is a signal of
increased mortality associated with glutamine administration. Given this conflicting
evidence, burn practitioners are either harming or saving lives with glutamine use. We
hypothesize that the inexpensive therapeutic strategy tested in this multicenter randomized
controlled clinical trial of supplemental enteral glutamine in 2700 severe burn injury
patients will lead to lower morbidity and mortality and reduced health care costs in an
otherwise very devastating and disabling injury worldwide.

In our pilot study (Critical Care Medicine, 2003, 31:2444) we found a protective effect of
glutamine against blood infection in severely burned adult patients. In addition, a
significant decrease in mortality was observed with glutamine. These results should be tested
with a multi-center trial because our study was small and did not have mortality as an end
point.

The specific aims of the study are to determine the overall treatment effect and safety of
glutamine in burn patients. Clinical outcomes will be: mortality, time to discharge alive,
incidence of acquired bacteremia due to Gram negative organisms, hospital mortality, duration
of mechanical ventilation, ICU stay and hospital stay. The cost-effectiveness of glutamine
administration will also be measured if the results show a decrease in length of care or a
reduced incidence of acquired bacteremia due to Gram negative organisms with glutamine.

The study will be a large, multicenter, double-blind, pragmatic, randomized controlled trial
of 2,700 patients with severe burns randomly allocated to receive enteral glutamine or
placebo. Randomization will be concealed and stratified by site allocating patients 1:1 to
either glutamine or matching placebo by the method of permuted blocks of random undisclosed
size within strata. Patients will be adults, a minimum of 18 years old, with deep 2nd and/or
3rd degree burns requiring grafting, and for patients age 18 - 39 years a (Total Body Surface
Area) TBSA burn ≥ 20% or in the presence of an inhalation injury a minimum of 15% TBSA burn
is required; for patients age 40 - 59 years a TBSA burn ≥ 15% is required; for patients aged
60 years or older a TBSA burn ≥ 10% is required. The study will include approximately 80 burn
centers in Canada, the US, Europe and Latin America. Patients will receive glutamine or a
placebo through their feeding tube, every 4 hours or TID or QID if taking things by mouth,
for a total of 0.5 g/kg/day for patients with a BMI <35. Patients with a BMI ≥35 will receive
0.5 g/kg/day based on an obesity-adjusted body weight. The study intervention will be
administered until ≥7 days after the last successful grafting operation or until discharge
from acute care unit or 3 months from admission, whichever comes first. Resuscitation,
nutritional support, pain management, infection control and surgical care will be done
according to standardized procedures.

The Data will be collected and managed by a professional and centralized organization for
multi centres clinical research (Clinical Evaluation Research Unit, Kingston, Ontario,
Canada).

Inclusion Criteria:

1. Deep 2nd and/or 3rd degree burns requiring grafting

2. Patient meets one of the following 4 criteria:

1. Patients 18 - 39 years of age with ≥ 20% TBSA* burn

2. Patients 18 - 39 years of age with ≥ 15% TBSA* burn and with inhalation injury

3. Patients 40 - 59 years of age with ≥ 15% TBSA* burn

4. Patients ≥ 60 years of age ≥ 10% TBSA* *TBSA - Total Body Surface Area

Exclusion Criteria:

1. > 72 hrs from admission to ICU to time of consent.

2. Patients younger than 18 years of age.

3. a) Patients without known renal disease and renal dysfunction defined as a serum
creatinine >171 µmol/L or a urine output of less than 500 mL/last 24 hours (or 80
mL/last 4 hours if a 24 hour period of observation is not available).

b) Patients with acute on chronic renal failure (pre-dialysis) with an absolute
increase of >80 µmol/L from baseline or pre-admission creatinine or a urine output of
<500 mL/last 24 hours (or 80 mL/last 4 hours).

c) Patients with chronic renal failure on dialysis will be excluded.

4. Liver cirrhosis - Child-Pugh class C liver disease

5. Pregnant or lactating females.

6. Contra-indication for EN: intestinal occlusion or perforation, intra-abdominal injury.

7. Patients with injuries from high voltage electrical contact.

8. Patients who are moribund (not expected to survive the next 72 hours).

9. Patients with extreme body sizes: BMI < 18 or > 50

10. Enrollment in another industry sponsored ICU intervention study.

11. Received glutamine supplement for > 24 hrs prior to randomization

12. Known allergy to maltodextrin, corn starch, corn, corn products or glutamine.
We found this trial at
26
sites
Augusta, Georgia 30909
Principal Investigator: Bruce Friedman, MD
Phone: 706-364-2966
?
mi
from
Augusta, GA
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
(409) 772-1011
Principal Investigator: David Herndon
Phone: 409-770-6733
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
?
mi
from
Galveston, TX
Click here to add this to my saved trials
Akron, Ohio
Principal Investigator: John Crow
Phone: 330-543-4586
?
mi
from
Akron, OH
Click here to add this to my saved trials
Aurora, Colorado 80045
Principal Investigator: Arek Wiktor, MD
Phone: 720-848-0000
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Bridgeport, Connecticut
Principal Investigator: Alisa Salvetamel
Phone: 203-384-3998
?
mi
from
Bridgeport, CT
Click here to add this to my saved trials
Columbus, Ohio 43212
Principal Investigator: Larry Jones
Phone: 614-293-5710
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Steven Wolf
Phone: 214-648-2041
?
mi
from
Dallas, TX
Click here to add this to my saved trials
2330 Stanley Road
Fort Sam Houston, Texas 78234
Principal Investigator: Jennifer Gurney, MD
?
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
Gainesville, Florida 32610
Principal Investigator: David Mozingo
Phone: 352-273-5670
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
10 Corneel Heymanslaan
Ghent, 9000
Principal Investigator: Kirsten Colpaert, MD
?
mi
from
Ghent,
Click here to add this to my saved trials
Houston, Texas 77024
Principal Investigator: James Cross
Phone: 713-500-7181
?
mi
from
Houston, TX
Click here to add this to my saved trials
Iowa City, Iowa 52242
Principal Investigator: Lucy Wibbenmeyer, MD
Phone: 319-353-8435
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Lincoln, Nebraska
Principal Investigator: David Voigt
Phone: 402-483-7825
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
Los Angeles, California
Principal Investigator: Warren Garner
Phone: 613-540-1089
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Memphis, Tennessee 38163
Principal Investigator: William Hickerson, MD
Phone: 901-448-2579
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Milwaukee, Wisconsin
Principal Investigator: Nicholas Meyer
Phone: 414-319-3000
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
4242 Dewey Ave
Omaha, Nebraska 68105
(800) 922-0000
Principal Investigator: Jessica Summers
Nebraska Medical Center Formed in 1997 by combining the operations of University Hospital, Bishop Clarkson...
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Phoenix, Arizona 85008
Principal Investigator: Kevin Foster
Phone: 602-344-5624
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15224
Principal Investigator: Ariel Aballay
Phone: 412-578-1836
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Portland, Oregon 97232
Principal Investigator: Nathan A Kemalyan, MD
Phone: 503-413-4232
?
mi
from
Portland, OR
Click here to add this to my saved trials
Sacramento, California 95817
Principal Investigator: Tina Palmieri, MD
Phone: 916-453-2050
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63141
Principal Investigator: Jonathan Pollack, MD
Phone: 314-251-5570
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Sam Mandell
Phone: 206-744-3410
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Tampa, Florida
Principal Investigator: David Smith
Phone: 813-974-7096
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Washington, District of Columbia 20010
Principal Investigator: Jeffery Shupp
Phone: 202-877-7347
?
mi
from
Washington,
Click here to add this to my saved trials
1 Medical Center Blvd
Winston-Salem, North Carolina 27157
336-716-2011
Principal Investigator: James Holmes
Phone: 336-716-0549
Wake Forest University Health Sciences Welcome to Wake Forest Baptist Medical Center, a fully integrated...
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials